Mohammad Abdallah1, Mohammad Badawi2, Mohammad Faisal Amirah3, Akram Rasheed3, Ahmed F Mady4, Mohammed Alodat4, Abdurahman Alharthy4. 1. Pharmaceutical Care Services, King Saud Medical City, Riyadh, Saudi Arabia. 2. Infection Control Department, King Saud Medical City, Riyadh, Saudi Arabia. 3. Nursing Education and Development Department, King Saud Medical City, Riyadh, Saudi Arabia. 4. Intensive Care Unit, King Saud Medical City, Riyadh, Saudi Arabia.
Abstract
BACKGROUND: Rates of carbapenem-resistant Pseudomonas aeruginosa are increasing. Aggressive prevention strategies, including instituting antimicrobial stewardship programmes, are essential for combating antimicrobial resistance. OBJECTIVES: We conducted this study to compare the antimicrobial susceptibility pattern of P. aeruginosa before and after carbapenem restriction. METHODS: We conducted a two-phase retrospective study in an adult ICU. The first phase was from May until July 2016 (before carbapenem restriction), whereas the second phase was from September until November 2016 (while implementing carbapenem restriction). The antimicrobial susceptibility pattern of P. aeruginosa was reviewed in August and December 2016. The measure of carbapenem-resistant P. aeruginosa was the proportion of resistant isolates (percentage resistant). The measure of antibacterial consumption in the study phases was DDDs/1000 patient days. RESULTS: The overall carbapenem consumption decreased significantly in the second phase, from 28.44 to 11.67 DDDs/1000 patient days (P = 0.012). The resistance of P. aeruginosa to imipenem and meropenem decreased significantly from 76.0% to 38.5% (P = 0.019) and from 74.1% to 30.0% (P = 0.012), respectively. Susceptibility of P. aeruginosa to other antibacterials was not affected by carbapenem restriction. CONCLUSIONS: These data suggest that restricting carbapenems, even for a short duration, may be an effective strategy for managing the problem of carbapenem resistance in P. aeruginosa.
BACKGROUND: Rates of carbapenem-resistant Pseudomonas aeruginosa are increasing. Aggressive prevention strategies, including instituting antimicrobial stewardship programmes, are essential for combating antimicrobial resistance. OBJECTIVES: We conducted this study to compare the antimicrobial susceptibility pattern of P. aeruginosa before and after carbapenem restriction. METHODS: We conducted a two-phase retrospective study in an adult ICU. The first phase was from May until July 2016 (before carbapenem restriction), whereas the second phase was from September until November 2016 (while implementing carbapenem restriction). The antimicrobial susceptibility pattern of P. aeruginosa was reviewed in August and December 2016. The measure of carbapenem-resistant P. aeruginosa was the proportion of resistant isolates (percentage resistant). The measure of antibacterial consumption in the study phases was DDDs/1000 patient days. RESULTS: The overall carbapenem consumption decreased significantly in the second phase, from 28.44 to 11.67 DDDs/1000 patient days (P = 0.012). The resistance of P. aeruginosa to imipenem and meropenem decreased significantly from 76.0% to 38.5% (P = 0.019) and from 74.1% to 30.0% (P = 0.012), respectively. Susceptibility of P. aeruginosa to other antibacterials was not affected by carbapenem restriction. CONCLUSIONS: These data suggest that restricting carbapenems, even for a short duration, may be an effective strategy for managing the problem of carbapenem resistance in P. aeruginosa.
Authors: Jean-François Timsit; Matteo Bassetti; Olaf Cremer; George Daikos; Jan de Waele; Andre Kallil; Eric Kipnis; Marin Kollef; Kevin Laupland; Jose-Artur Paiva; Jesús Rodríguez-Baño; Étienne Ruppé; Jorge Salluh; Fabio Silvio Taccone; Emmanuel Weiss; François Barbier Journal: Intensive Care Med Date: 2019-01-18 Impact factor: 17.440
Authors: Kamini Walia; Jayaprakasam Madhumathi; Balaji Veeraraghavan; Arunaloke Chakrabarti; Arti Kapil; Pallab Ray; Harpreet Singh; Sujatha Sistla; V C Ohri Journal: Indian J Med Res Date: 2019-02 Impact factor: 2.375
Authors: Saad Alhumaid; Abbas Al Mutair; Zainab Al Alawi; Ahmad J Alzahrani; Mansour Tobaiqy; Ahmed M Alresasi; Ibrahim Bu-Shehab; Issa Al-Hadary; Naif Alhmeed; Mossa Alismail; Ahmed H Aldera; Fadhil AlHbabi; Haifa Al-Shammari; Ali A Rabaan; Awad Al-Omari Journal: Ann Clin Microbiol Antimicrob Date: 2021-06-12 Impact factor: 3.944
Authors: Corné H W Klaassen; Juliëtte A Severin; Andreu Coello Pelegrin; Yulia Rosa Saharman; Aurélien Griffon; Mattia Palmieri; Caroline Mirande; Anis Karuniawati; Rudyanto Sedono; Dita Aditianingsih; Wil H F Goessens; Alex van Belkum; Henri A Verbrugh Journal: mBio Date: 2019-11-12 Impact factor: 7.867
Authors: Tiago Zequinão; João Paulo Telles; Juliano Gasparetto; Felipe Francisco Tuon Journal: Rev Soc Bras Med Trop Date: 2020-11-06 Impact factor: 1.581